Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Actuate Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ACTU alerts

About Daniel M. Schmitt

Daniel M. Schmitt is recorded as Board Member and CEO at Actuate Therapeutics, Inc. (ACTU). The newest filing on record that lists Daniel M. Schmitt as Board Member and CEO at Actuate Therapeutics, Inc. (ACTU) is dated April 6, 2026. The proxy statement of Actuate Therapeutics, Inc. reports total compensation of $2,166,522 for Daniel M. Schmitt in fiscal 2025, including a base salary of $570,000. Disclosed compensation is on record for 3 fiscal years. Actuate Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Actuate Therapeutics, Inc. includes Paul Lytle (CFO), Andrew P. Mazar (COO), Aaron G.L. Fletcher (Board Member) and 7 others.

Affiliation history

Company network

Leadership on record at Actuate Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Actuate Therapeutics, Inc. (ACTU) $570,000 $2,166,522
2024 Actuate Therapeutics, Inc. (ACTU) $400,000 $5,578,616
2023 Actuate Therapeutics, Inc. (ACTU) $400,000 $520,000

Recent activity

No call appearances or filed executive changes recorded yet.